Amyotrophic Lateral Sclerosis News and Research

RSS

Preliminary data from Phase 2 clinical trial of ZFP Therapeutic program presented

Sangamo BioSciences, Inc. announced today the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for amyotrophic lateral sclerosis (ALS) at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany.

9 Dec 2009

Clinical results from Phase 2 study of KNS-760704 presented by Knopp Neurosciences

Knopp Neurosciences Inc. (“Knopp”) announced the presentation today of encouraging clinical results in a Phase 2 safety and tolerability study of KNS-760704 in amyotrophic lateral sclerosis (“ALS”).

9 Dec 2009

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

The Cedars-Sinai Regenerative Medicine Institute is to provide stem cells to a five-member National Institutes of Health consortium of researchers for development of potential therapies to treat Huntington's disease.

8 Dec 2009

FDA approves revised clinical trial protocol for CytRx' arimoclomol

CytRx Corporation, a biopharmaceutical company, is permitted to re-enter the clinic with its orally administered molecular chaperone drug candidate arimoclomol as a therapeutic treatment for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), following the U.S. Food and Drug Administration’s (FDA) acceptance of a revised clinical trial protocol.

2 Dec 2009

Neurotoxic heavy metal can slow the progression of Lou Gehrig's disease

New discoveries have been made about how an elevated level of lead, which is a neurotoxic heavy metal, can slow the progression of amyotrophic lateral sclerosis, or Lou Gehrig's disease - findings that could point the way to a new type of therapy.

1 Dec 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Copper sequestering drug tetrathiomolybdate shown to be effective in treating Wilson disease

The copper sequestering drug tetrathiomolybdate (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload of copper, and certain metastatic cancers.

27 Nov 2009

Image of a water flea wins top prize in the 2009 Olympus BioScapes Digital Imaging Competition

A glowing, eerily beautiful image of a water flea with its radiant green "crown of thorns" took top prize in the 2009 Olympus BioScapes Digital Imaging Competition®, the world's foremost forum for showcasing microscope photos and movies of life science subjects. Dr. Jan Michels, a zoologist at the University of Albrecht, Kiel, Germany, took top honors for the image of a water flea, with its defensive "crown of thorns" to protect it against predators. The image reveals not only the exoskeleton, but also interior detail down to the nuclei within its cells, seen as tiny, glowing blue dots. This

From Evident Corporation - Life Sciences 20 Nov 2009

Neuralstem provides financial and business updates for third-quarter 2009

Neuralstem, Inc. today provided a financial and business update for the third quarter ended September 30, 2009.

17 Nov 2009

Study establishes link between smoking and Amyotrophic Lateral Sclerosis

While previous studies have indicated a "probable" connection between smoking and ALS, a new study published in the Nov. 17, 2009 issue of Neurology-, the medical journal of the American Academy of Neurology, states that smoking may now be considered an "established" risk factor for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease.

17 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

Daval International receives award for its anti-inflammatory agent AIMSPRO

Following the provision of clinical and scientific data to the US Food and Drug Administration (FDA), privately owned UK company Daval International Limited (http://www.davalinternational.com) has been informed that its innovative anti-inflammatory agent AIMSPRO(R) has been awarded an Orphan-Drug designation for the treatment of Amyotrophic Lateral Sclerosis (ALS).

9 Nov 2009

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors.

30 Oct 2009

CytRx study reveals potential of molecular chaperones in design of anti-aging pharmaceuticals

CytRx Corporation, a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals.

29 Oct 2009

CIRM awards Salk Institute $10.8M grant to develop stem-cell based therapy for Lou Gehrig's Disease

The Salk Institute has been awarded a $10.8 million grant by the California Institute for Regenerative Medicine (CIRM) for translational research focusing on developing a novel stem-cell based therapy for Amyotrophic Lateral Sclerosis (ALS) - or Lou Gehrig's Disease.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

APC enzyme may be effective for treating amyotrophic lateral sclerosis

A chemical cousin of a drug currently used to treat sepsis dramatically slows the progression of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, in mice. The results offer a bit of good news in efforts to develop a therapy to stop or slow the progression of a disease that generally kills its victims within just a few years.

26 Oct 2009

H.R. 3790 wins praises in Pennsylvania

The Pennsylvania Association of Medical Suppliers and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the misguided and deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare. The bidding process in this controversial program began on October 21 in the Pittsburgh metropolitan statistical areas and seven other MSAs across the U.S.

23 Oct 2009

Bill eliminating the flawed medical equipment bidding process in the Riverside-San Bernardino area lauded

The California Association of Medical Product Suppliers and the American Association for Homecare praised a bipartisan bill in Congress, H.R. 3790, to eliminate the misguided and deeply flawed "competitive" bidding program for durable medical equipment and services in Medicare.